by Truveta Research | Jun 13, 2025 | Research, Research Insights
Truveta and collaborators partnered on a new large-scale study that considers the potential benefits of GLP-1 RA for AUD, among those with diabetes and/or obesity. Using a target trial emulation framework, researchers analyzed Truveta Data and compared adults with...
by Truveta Research | Jun 11, 2025 | Research, Research Insights
Timely receipt of the MMR vaccine for children has been declining since 2021, with just 76.9% of children receiving the MMR vaccine in 2024 on time. The odds of non-vaccination by age two for measles were higher among male children, children in rural areas, White...
by Truveta Research | Jun 5, 2025 | Research, Research Insights
The percentage of uncemented total knee arthroplasties (TKAs) nearly doubled from 5.7% to 10.3% between 2018 and 2024. Readmission and revision rates were similar between cemented and uncemented TKAs. Cemented TKAs were associated with higher rates of stiffness,...
by Truveta Research | Jun 3, 2025 | Research, Research Insights
In collaboration with Reuters, Truveta Research explored trends in FDA-approved anti-obesity GLP-1 RA prescriptions among adolescents. Among the 1,265,399 adolescents (aged 12-17 years) in this study, the average rate of first-time AOM semaglutide prescriptions was...
by Truveta staff | May 30, 2025 | Research, Research Insights
Authors: Wilson Lau, PhD ⊕Truveta, Inc, Bellevue, WA,, Youngwon Kim, PhD ⊕Truveta, Inc, Bellevue, WA, Sravanthi Paras, MD ⊕Swedish Medical Center, Seattle, WA, Md Enamul Haque, PhD ⊕Truveta, Inc, Bellevue, WA,, Sara Daraei, PhD ⊕Truveta, Inc, Bellevue, WA, Rajesh Rao,...
by Truveta Research | May 30, 2025 | Research, Research Insights
Authors: Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA Duy Do, PhD ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Jennifer Liang, MD ⊕Truveta, Inc, Bellevue, WA, Keenan Robbins, MBBS ⊕Washington University...
by Truveta staff | May 29, 2025 | Data
Each year, more than 34,000 men in the U.S. die from prostate cancer. While early-stage disease is often highly treatable, outcomes still vary widely — especially by race, income, and geography. Catching the disease early can save lives, but real-world data on...
by Sujatha Sagiraju | May 22, 2025 | Technology
As machine learning models increasingly assist in interpreting patient records, understanding how to properly evaluate these models becomes crucial for ensuring reliable clinical research outcomes. Jay Nanduri, Truveta CTO, provided an overview of Truveta language...
by Truveta staff | May 21, 2025 | Research
A recent analysis using Truveta Data reveals that patients undergoing high-risk, non-emergency heart procedures (percutaneous coronary intervention, or PCI) with support from the Impella heart pump had better outcomes than those supported with an intra-aortic balloon...
by Truveta Research | May 16, 2025 | Research, Research Insights
Among children in Texas receiving a first measles vaccine prior to two years of life: In March and April 2025, 20.1% of all first measles vaccines were administered to children early (6-11 months). This is 11.5-fold higher than in 2019, when there were international...
